Novartis ready for any flu fights

Gordon, Michael
July 2006
ICIS Chemical Business;7/31/2006, Vol. 1 Issue 30, p29
Trade Publication
The article reports on the plans by Novartis to build the first cell culture-derived influenza vaccine manufacturing plant in Holly Springs, North Carolina. The $600 million facility will be able to produce 50 million doses/year of seasonal trivalent flu vaccines. In an event of an influenza pandemic, the site is planned to expand production to 150 million doses/year within six months of a declaration.


Related Articles

  • Agriflu.  // Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p11 

    The article reports on the approval of Novartis AG's Agriflu, vaccines for prevention of influenza virus subtypes A and B.

  • US pushes into cell-based vaccines.  // TCE: The Chemical Engineer;Dec2009/Jan2010, Issue 822/823, p12 

    The article reports on the 1 billion U.S. dollar that will be invested by Novartis and the U.S. government to make the first cell culture-based flu vaccine production facility in the country operational.

  • FDA licenses Novartis facility to produce cell-based influenza vaccines.  // Infectious Disease News;Jul2014, Vol. 27 Issue 7, p52 

    The article reports that Novartis has announced that the U.S. Food and Drug Administration (FDA) has licensed its manufacturing facility in Holly Springs, North Carolina for the production of cell-based influenza vaccines.

  • From Dream to Reality. STARNER, RON // Site Selection;Nov/Dec2011, Vol. 56 Issue 6, p904 

    The article focuses on how North Carolina helped pharmaceutical firm Novartis AG in opening an innovative 1 billion dollars flu vaccine plant in Holly Springs. The facility, expected to be operational in 2013, will create 400 new jobs and will produce 150 million doses of pandemic influenza...

  • Cell-based vaccines yield only modest advances for seasonal flu. Willyard, Cassandra // Nature Medicine;Jan2013, Vol. 19 Issue 1, p4 

    The article discusses the advances in producing influenza vaccines using new eggless manufacturing techniques. It informs that the U.S. Food and Drug Administration has approved the first influenza vaccine, Flucelvax, a seasonal flu vaccine, produced by Novartis AG in dog kidney cells. It...

  • Switzerland & Canada lift ban on Novartis flu vaccines.  // Reactions Weekly;11/10/2012, Issue 1427, p3 

    The article reports on the decision of Health Canada and Swissmedic to lift the ban on the distribution of Novartis seasonal influenza vaccines Agrippal and Fluad in Canada and Switzerland.

  • Novartis 4Q Net Falls on Lower Vaccine Sales, Charges.  // MondayMorning;1/31/2011, Vol. 19 Issue 4, p3 

    The article reports on the financial performance of Novartis AG. Fourth-quarter profit fell to 6 percent as sales of influenza vaccine declined following the end of the flu pandemic. The stock also fell the most in almost seven months. Net income dropped to 2.17 billion dollars from 2.31 billion...

  • New Hope for Worldwide Influenza Vaccine Supply. Harrison, Brianne // Pharmaceutical Technology;Jun2007, Vol. 31 Issue 6, p26 

    The article presents the importance of new the cell culture-derived influenza vaccine by Novartis AG in meeting the pandemic vaccine demand in Geneva, Switzerland. The World Health Organization (WHO) and the Committee for Medicinal Products for Human Use approve the Novartis new cell...

  • Novartis: higher bid to secure Chiron deal.  // PharmaWatch: Monthly Review;May2006, Vol. 5 Issue 5, p50 

    The article reports that Novartis AG has increased its bid to acquire the world's leading vaccine producers Chiron Corp. in order to hasten completion of the deal. The new bid that amounts to $5.3 billion is expected to appease the company shareholders and helps Novartis to strengthen its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics